Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

BofA Securities maintained a Buy rating on Eli Lilly stock (NYSE:LLY), with a price target set at $997.00. With a market capitalization of $706 billion and impressive revenue growth of 27.4% over the ...

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...

Novo Nordisk's experimental obesity drug, amycretin, displayed impressive results, causing a 22% weight loss in participants over 36 weeks. The news boosted Novo’s shares and highlights its potential ...

Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...

Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

Charting, Price Performance, News & Related Contracts.

There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.jCr9XYTz.js ...